Login / Signup
Tuning spacer length improves the functionality of the nanobody-based VEGFR2 CAR T cell.
Fatemeh Hajari Taheri
Mahmoud Hassani
Zahra Sharifzadeh
Mahdi Behdani
Shahryar Abdoli
Mahtab Sayadi
Kowsar Bagherzadeh
Arash Arashkia
Mohsen Abolhassani
Published in:
BMC biotechnology (2024)
The results demonstrated that the third-generation anti-VEGFR2 nanobody-based CAR T cell with a long spacer had a superior function and potentially could be a better candidate for solid tumor treatment.
Keyphrases
</>
vascular endothelial growth factor